TrialScientific reports2023

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.

Fumihiko Koiwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.